What Is Immunology Testing and What Is It Used For?

Immunology testing is a broad category of laboratory work that measures how your immune system is functioning or reacting to specific threats. These tests detect antibodies, antigens, immune cells, and other immune markers in blood or tissue samples, and they are used across nearly every corner of medicine: diagnosing infections, identifying autoimmune diseases, screening for allergies, evaluating immune deficiencies, matching organ transplants, and guiding cancer treatment. The underlying principle is deceptively simple, but the range of clinical applications is enormous and still expanding.

The Basic Mechanism Behind Immunology Tests

Most immunology tests rely on the same core interaction: the highly specific binding between an antibody and an antigen. An antibody is a protein your immune system produces in response to something it recognizes as foreign (or, in autoimmune conditions, something it mistakenly treats as foreign). An antigen is the substance that triggers that response. In a lab setting, scientists exploit this lock-and-key pairing to detect and measure either side of the equation. A test might use a known antigen to capture antibodies from your blood, or use a known antibody to identify an antigen in a sample.¹

The sensitivity and accuracy of any immunology test depend on the quality of the antibodies used, how tightly they bind to their target, and the detection method layered on top. Some tests use fluorescent labels that glow under certain light. Others use enzymes that trigger a color change, as in the well-known ELISA format. Still others measure electrical signals or light emissions from chemical reactions. These differences in detection technology shape how immunology tests are applied in practice and how reliable they are in different clinical situations.

Diagnosing Infections

One of the most common reasons doctors order immunology testing is to find out whether you have been infected by a particular pathogen. When your body encounters a virus or bacterium, it produces antibodies against it. The first wave of antibodies, called IgM, tends to appear quickly and then decline. A second wave, IgG, builds more slowly but sticks around much longer, sometimes for years. By measuring the levels of each, a lab can often distinguish between a recent infection and one that happened months or years ago.

This timeline matters clinically. In scrub typhus, for instance, IgM antibodies can stay above the diagnostic threshold for up to 12 months after the infection clears, while IgG levels keep rising for about 10 months before gradually declining over years. That means a single blood draw showing elevated IgM does not necessarily mean you are currently sick; it could reflect an infection from several months back. IgG, on the other hand, serves as a more reliable marker of past exposure.²

Timing creates a different kind of problem in blood-bank screening. Traditional immunoassays for hepatitis B, hepatitis C, and HIV detect antibodies or antigens that appear only after the body has had time to mount a response. During the early days of infection, those markers have not built up to detectable levels. This gap, known as the window period, can last weeks. For hepatitis B, antibody-based assays miss infections during a window that can stretch beyond 35 days, while nucleic acid testing (which looks for viral genetic material rather than immune markers) can shorten that gap substantially.³ Adding nucleic acid testing to blood-screening programs reduces the residual risk of transfusion-transmitted hepatitis B by closing part of that window period.⁴ This is one of the clearest illustrations of where immunology testing has limits, and where combining it with other methods fills the gap.

Autoimmune Disease Workups

When the immune system turns against the body’s own tissues, immunology testing becomes essential for figuring out what is going wrong. The starting point for many autoimmune evaluations is the antinuclear antibody (ANA) test, which detects antibodies directed at components inside the cell nucleus. How the antibodies bind, and the visual pattern they produce under a fluorescence microscope, gives clinicians clues about which disease might be responsible.

A study evaluating ANA-positive samples found that about two-thirds showed nuclear staining patterns and a third showed cytoplasmic patterns. Among nuclear-pattern positives, the speckled pattern was by far the most common, followed by homogeneous, nucleolar, and centromere patterns. Different patterns correlate with different diseases: centromere patterns are associated with systemic sclerosis, while homogeneous and speckled patterns tend to show up in lupus and Sjögren’s disease. Follow-up testing to identify the specific autoantibody (anti-Ro52, anti-Ro60, anti-dsDNA, and others) narrows the diagnosis further.⁵

Autoimmune testing can also reveal unexpected overlaps. In a cohort of patients with joint pain or gastrointestinal symptoms, researchers tested for markers of both rheumatoid arthritis and celiac disease. Among those who were seropositive for rheumatoid arthritis markers, about 8% also tested positive for celiac disease, and a much larger proportion (roughly 83%) showed reactivity to wheat proteins on a broader panel. That kind of overlap highlights why clinicians sometimes cast a wide net with immunology panels rather than ordering a single test in isolation.⁶

Allergy Testing

Allergy-related immunology testing works by detecting IgE, the class of antibody your body produces in response to allergens. Blood-based allergy tests measure allergen-specific IgE in serum, while skin prick tests introduce tiny amounts of allergen under the skin and look for a local reaction. Both approaches try to answer the same question, but they do not always agree.

In a study of latex allergy, skin testing confirmed a positive allergy history in 86% of symptomatic patients, compared to just 49% for serum-based IgE detection. The blood tests had good negative predictive value, meaning that a negative result was reassuring, but they lacked the sensitivity of skin testing. Among patients with clear IgE-mediated symptoms following latex exposure who tested positive on skin prick, only about half also showed positive results on the blood assay.⁷ In practice, this means your doctor may prefer one test over the other depending on the situation, and a negative blood test alone does not always rule out an allergy.

Evaluating Immune Deficiencies

Some people get infections more frequently, more severely, or from unusual organisms. When that pattern raises suspicion for an underlying immune deficiency, immunology testing helps identify which arm of the immune system is compromised. Initial screening typically includes a complete blood count (to look at white blood cell numbers), measurement of serum immunoglobulin levels (IgG, IgA, IgM, IgE), vaccine-response titers, and complement activity.⁸ These tests together give a snapshot of whether the body is producing enough antibodies, whether those antibodies actually work against known vaccines, and whether the complement system (a set of proteins that help antibodies clear infections) is intact.⁹

If initial screening results are abnormal, the workup deepens. Counting specific types of lymphocytes (T cells, B cells, natural killer cells) can reveal deficits in cellular immunity rather than antibody production. More specialized functional tests, and increasingly genetic sequencing, can identify the precise molecular defect responsible for a primary immunodeficiency.¹⁰ These diagnoses matter because treatment varies dramatically depending on which component is missing: some patients need regular immunoglobulin infusions, others need bone marrow transplants, and some benefit from targeted therapies aimed at a specific genetic pathway.

Transplant Compatibility

Before an organ transplant, immunology testing determines whether the recipient’s immune system is likely to attack the donor organ. The key players are human leukocyte antigens (HLAs), proteins on cell surfaces that the immune system uses to distinguish “self” from “foreign.” If the recipient has pre-existing antibodies against the donor’s HLA types, the risk of rejection is high.¹¹

The crossmatch test is the critical compatibility check. Traditional physical crossmatch methods involve mixing the patient’s serum with actual donor cells and watching for a reaction, which is labor-intensive and logistically difficult, especially when organs need to be matched quickly across long distances. A newer approach called virtual crossmatch sidesteps the need to physically combine samples. Instead, it analyzes the recipient’s anti-HLA antibody profile and the donor’s HLA type independently, then compares the results computationally to predict compatibility.¹² Virtual crossmatching has sped up the organ allocation process considerably, though physical crossmatching remains the definitive test in many transplant centers.

Cancer Immunotherapy Guidance

Immunology testing plays a growing role in cancer treatment, particularly in deciding who should receive immune checkpoint inhibitor drugs. These drugs work by blocking proteins (like PD-L1) that tumors use to hide from the immune system. Testing a tumor biopsy for PD-L1 expression helps oncologists predict whether a patient is likely to respond to these therapies.

The reality is more complicated than “positive means the drug works.” An analysis of FDA approvals for immune checkpoint inhibitors found that PD-L1 expression was predictive of response in only about 29% of approval contexts. In the rest, it was either not predictive or had not been tested at all.¹³ This has pushed researchers to look at combining multiple biomarkers. A systematic review and meta-analysis comparing different approaches found that multiplex immunohistochemistry and immunofluorescence outperformed single-marker PD-L1 testing. Combining several modalities brought the predictive accuracy closer to that of the more advanced multiplex methods.¹⁴ For patients, this means that a single PD-L1 test result should not be the sole factor in treatment decisions.

Measuring Cellular Immunity

Not all immune protection comes from antibodies. T cells, a type of white blood cell, are central to fighting off infections and destroying abnormal cells. Testing T-cell responses requires different tools than antibody-based tests. Interferon-gamma release assays (IGRAs) are the best-established method. They work by exposing a blood sample to specific pathogen-derived proteins and then measuring whether T cells respond by releasing interferon-gamma, a signaling molecule that indicates immune recognition.

IGRAs have long been the standard for diagnosing tuberculosis exposure, and the same principle was adapted during the COVID-19 pandemic to measure cellular immunity against SARS-CoV-2. Researchers used interferon-gamma release assays to detect T-cell responses to SARS-CoV-2 spike and nucleocapsid proteins, providing a way to assess immunity beyond what antibody tests alone could reveal.¹⁵ This was especially relevant for people whose antibody levels had dropped but who might still have been protected through cellular immunity.¹⁶

Flow cytometry takes cellular immune assessment a step further. By tagging cells with fluorescent antibodies that bind to specific surface markers, researchers can identify and count dozens of immune cell populations in a single blood draw. Standardized panels using 51 or more surface antibodies can profile the full landscape of someone’s immune cells, revealing not just how many of each type are present but also their functional state.¹⁷ This kind of deep immunophenotyping is used in research, in monitoring patients with immune deficiencies, and increasingly in guiding immunotherapy for cancer.

Things That Can Go Wrong With Results

Immunology tests are powerful, but they are not infallible. One well-known pitfall involves heterophile antibodies, which are non-specific antibodies in your blood that can bind to components of the test itself and produce falsely elevated results. In one study examining a multiplex cytokine assay, heterophile antibodies caused significantly inflated cytokine readings compared to normal samples. Internal controls built into the assay were needed to flag and identify the false signals.¹⁸ Not every assay has those safeguards, which is part of why clinicians learn to interpret immunology results in context rather than taking a single number at face value.

The window period problem described earlier in the context of blood screening applies more broadly. Any infection has a phase early on when the immune response has not yet produced enough antibodies to be detectable. Testing too early yields a false negative. This is why doctors sometimes order a repeat test weeks later, or combine antibody-based immunology tests with direct pathogen detection methods like PCR.

Rapid and Point-of-Care Immunology Tests

Lateral flow assays, the technology behind home pregnancy tests and rapid COVID-19 antigen tests, are the most stripped-down version of immunology testing. A sample (blood, saliva, or nasal swab) wicks along a paper strip past lines of immobilized antibodies or antigens. If the target molecule is present, a visible line appears. These tests are inexpensive, require no lab equipment, and deliver results in minutes, making them valuable in settings with limited resources.¹⁹

The trade-off is sensitivity. Traditional lateral flow assays are orders of magnitude less sensitive than lab-based ELISA or PCR. They work best when the target molecule is present in high concentrations, which is why rapid antigen tests for COVID-19 were most reliable during the first few days of symptoms when viral load peaks. Researchers are working on next-generation lateral flow designs using advanced nanomaterials and signal amplification strategies to close the sensitivity gap, but for now, a negative rapid test does not carry the same weight as a negative lab-based result.²⁰

Prenatal Antibody Screening

Every pregnant person in most healthcare systems gets immunology testing early in pregnancy. The standard first-trimester panel includes blood typing (ABO and RhD) and an antibody screen. The antibody screen checks whether the mother’s blood contains antibodies against red blood cell antigens that could cross the placenta and attack the baby’s red blood cells, a condition called hemolytic disease of the fetus and newborn. While antibodies to red blood cell antigens are relatively uncommon, early identification allows high-risk pregnancies to be monitored closely and managed by specialists.²¹

The most familiar example involves Rh incompatibility: an Rh-negative mother carrying an Rh-positive baby can develop anti-D antibodies after exposure to the baby’s blood. Immunology testing detects these antibodies and tracks their levels throughout the pregnancy. If titers rise above a critical threshold, interventions such as intrauterine transfusion may be needed. The widespread use of Rh immune globulin (RhoGAM) has dramatically reduced the incidence of this problem, but routine antibody screening remains standard practice because other, less common antibodies can cause the same disease.

Multiplex Testing and Cytokine Profiling

Traditional ELISA-based immunology tests measure one molecule at a time: one antibody, one antigen, one cytokine. Multiplex platforms have changed this by allowing simultaneous measurement of dozens of targets in a single sample. This capability is especially useful for cytokine profiling, where the goal is to capture the full inflammatory signature rather than a single marker. Multiplex arrays offer substantial savings in both sample volume and cost compared to running separate ELISAs for each cytokine of interest.²²

The clinical potential of multiplex cytokine panels extends beyond infection and inflammation. Researchers have used these platforms to measure 24 cytokines simultaneously in ovarian cancer patients, healthy controls, and women with benign pelvic tumors, exploring whether a multi-marker cytokine profile could help detect ovarian cancer earlier than single-marker tests like CA-125.²³ The principle is that a panel of markers captures the complexity of the immune response better than any single measurement can. This same logic drives the push toward multi-biomarker panels in immunotherapy response prediction, transplant monitoring, and autoimmune disease management.

Monitoring Biologic Drug Therapy

A newer application of immunology testing involves monitoring patients on biologic drugs, particularly monoclonal antibody therapies used for conditions like rheumatoid arthritis and inflammatory bowel disease. Because these drugs are themselves antibodies, the body can develop its own antibodies against them, called anti-drug antibodies. When anti-drug antibodies form, the medication may become less effective or cause adverse reactions.

Therapeutic drug monitoring uses immunoassays to measure both the circulating level of the biologic drug and the presence of anti-drug antibodies. Label-free immunoassay technologies have been developed for drugs like adalimumab and infliximab that can quantify active drug levels and detect anti-drug antibodies without the labeling steps required by traditional assays.²⁴ For patients, this kind of monitoring can inform whether a dose needs adjusting or whether switching to a different drug makes more sense than increasing the dose of one the body is already rejecting.